

10/03/0181
J0003 PCT/PTC 04 FEB 2002

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

The Accompanying Application

Applicants : LIEBESCHUETZ, John Walter
MURRAY, Christopher William
YOUNG, Stephen Clinton
CAMP, Nicholas Paul
JONES, Stuart Donald
WYLIE, William Alexander
MASTERS, John Joseph
WILEY, Michael Robert
SHEEHAN, Scott Martin
ENGEL, David Birenbaum
WATSON, Brian Morgan
GUZZO, Peter Robert
MAYER, Michael John

Entry into National Phase of International Application No.:
PCT/GB01/02553 under 35 U.S.C. § 371
For : SERINE PROTEASE INHIBITORS
Docket No. : 00219US

PRELIMINARY AMENDMENT ON FILING

Attention: DO/EO
Box PCT
Assistant Commissioner for Patents
Washington, DC 20231

Sir:

Before calculating the filing fee, please amend the

10030181-020402

Marked Up Version of Claims
Claims

$$\begin{array}{c} \text{Cy} \\ | \\ \text{R}_2 - \text{X} - \text{X} - \text{Y} - \text{L} - \text{Lp(D)}_n \end{array}$$

wherein:

R₂ is a 5 or 6 membered aromatic carbon ring optionally interrupted by a nitrogen, oxygen or sulphur ring atom, optionally being substituted in the 3 and/or 4 position (in relation to the point of attachment of X-X) by halo, nitro, thiol, haloalkoxy, hydrazido, alkylhydrazido, amino, cyano, haloalkyl, alkylthio, alkenyl, alkynyl, acylamino, tri or difluoromethoxy, carboxy, acyloxy, MeSO₂- or R₁, or the substituents at the 3 and 4 positions taken together form a fused ring which is a 5 or 6 membered carbocyclic or heterocyclic ring optionally substituted by halo, haloalkoxy, haloalkyl, cyano, nitro, amino, hydrazido, alkylthio, alkenyl, alkynyl or R_{1j}, and optionally substituted in the position alpha to the X-X group (i.e. 6 position for a six membered aromatic ring etc) by amino, hydroxy, halo, alkyl, carboxy, alkoxycarbonyl, cyano, amido, aminoalkyl, alkoxy or alkylthio with the proviso that R₂ cannot be aminoisoquinolyl;

each X independently is a C, N, O or S atom or a CO,

25 CR_{1a}, C(R_{1a})₂ or NR_{1a} group, at least one X being C, CO, CR_{1a}
or C(R_{1a})₂;

each R_{1a} independently represents hydrogen or hydroxyl, alkoxy, alkyl, aminoalkyl, hydroxyalkyl alkoxyalkyl, alkoxycarbonyl, alkylaminocarbonyl, alkoxycarbonylamino, acyloxymethoxycarbonyl or alkylamino optionally substituted by hydroxy, alkylamino, alkoxy, oxo, aryl or cycloalkyl;

R_1 is as defined for R_{1a} , provided that R_1 is not

unsubstituted aminoalkyl;

Y (the α -atom) is a nitrogen atom or a CR_{1b} group;

Cy is a saturated or unsaturated, mono or poly cyclic, homo or heterocyclic group, optionally substituted by groups

5 R_{3a} or R_{3i}X_i;


each R_{3a} independently is R_{1c}, amino, halo, cyano, nitro, thiol, alkylthio, alkylsulphonyl, alkylsulphenyl, triazolyl, imidazolyl, tetrazolyl, hydrazido, alkylimidazolyl, thiazolyl, alkylthiazolyl, alkylloxazolyl, oxazolyl, alkylsulphonamido, 10 alkylaminosulphonyl, aminosulphonyl, haloalkoxy, haloalkyl, a group of the formula -C(X³)N(R¹¹)R¹² (wherein X³ is O or S; and R¹¹ and R¹² are independently selected from hydrogen, methyl or ethyl or together with the nitrogen atom to which they are attached form a pyrrolidin-1-yl, piperidin-1-yl or 15 morpholino group), or -OCH₂O- which is bonded to two adjacent ring atoms in Cy;

X_i is a bond, O, NH or CH₂;

R_{3i} is phenyl, pyridyl or pyrimidinyl optionally substituted by R_{3a};

20 R_{1b}, R_{1c} and R_{1j} are as defined for R_{1a}; and

-L-Lp(D)_n is of the formula:




in which R_r is -(CH₂)_c-R_c, -CHReR_f, -CH₂-CHReR_f, -CH₂-CH₂-CHReR_f, or R_g in which c is 1 or 2; R_c is thienyl, 25 thiazolyl (which may bear an amino substituent), isothiazolyl, oxazolyl, isoxazolyl, pyrazolyl, imidazolyl, pyridyl (which may bear an alkylsulphonyl, aminosulphonyl, alkylaminosulphonyl, alkylaminocarbonyl, amino, amido, (1-4C)alkoxycarbonyl, carboxy, acetylamino, chloro, fluoro, 30 cyano, (1-3C)alkyl, trifluoromethyl, methoxy, ethoxy, nitro, hydroxy, alkylsulphonylamino, triazolyl or tetrazolyl

- 172 -

substituent), pyrimidinyl, pyridazinyl, pyrazinyl or phenyl (which may bear a methyl, methylamino, dimethylamino, carboxy, dialkylaminosulphonyl, alkylsulphonyl, aminosulphonyl, alkylaminosulphonyl, alkylaminocarbonyl, amino, amido, 5 alkoxy, acetyl, chloro, fluoro, cyano, methoxy, ethoxy, nitro, hydroxy, alkylsulphonylamino, triazolyl or tetrazolyl substituent); each of R_e and R_f independently is hydrogen or C_{1-3} alkyl; or CHR_eR_f is cyclopentyl (which may bear a hydroxy, amino, (1-3C)alkoxy, (1-3C)hydroxyalkyl, (1-10 3C)alkyl, carboxy, methoxycarbonyl or ethoxycarbonyl substituent at the 3- or 4-position), cyclohexyl (which may bear a hydroxy, amino, (1-3C)alkoxy, (1-3C)hydroxyalkyl, (1-3C)alkyl, carboxy, methoxycarbonyl or ethoxycarbonyl substituent at the 3- or 4-position), tetrahydropyran-4-yl, 15 tetrahydrothiopyran-4-yl, pyrrolidin-3-yl (which may bear a hydroxy, amino, (1-3C)alkoxy, (1-3C)hydroxyalkyl, (1-3C)alkyl, carboxy, methoxycarbonyl or ethoxycarbonyl substituent at the 1-position), piperidin-4-yl (which may bear a hydroxy, amino, (1-3C)alkoxy, (1-3C)hydroxyalkyl, (1-3C)alkyl, carboxy, 20 methoxycarbonyl or ethoxycarbonyl substituent at the 1-position), or indan-2-yl; and R_g is 2-methylsulphonylphenyl which may bear a 4-fluoro substituent or R_g is λ^6 -1,1-dioxobenzo[b]thiophen-7-yl;

or a physiologically-tolerable salt thereof;

25 provided that $Lp(D)_n$ is not of the formula (K):




wherein X_2 is fluoro or hydrogen.

30 compound according to claim 1

2. ~~A serine protease inhibitor compound of formula (I)~~

(amended)

- 173 -



wherein,

~~R₂ is a 5 or 6 membered aromatic carbon ring optionally~~
 5 interrupted by a nitrogen, oxygen or sulphur ring atom,
 optionally being substituted in the 3 and/or 4 position (in
 relation to the point of attachment of X-X) by halo, nitro,
 thiol, haloalkoxy, hydrazido, alkylhydrazido, amino, cyano,
 haloalkyl, alkylthio, alkenyl, alkynyl, acylamino, tri or
 10 difluoromethoxy, carboxy, acyloxy, MeSO₂- or R₁, or the
 substituents at the 3 and 4 positions taken together form a
 fused ring which is a 5 or 6 membered carbocyclic or
 heterocyclic ring optionally substituted by halo, haloalkoxy,
 haloalkyl, cyano, nitro, amino, hydrazido, alkylthio, alkenyl,
 15 alkynyl or R_{1j}, and optionally substituted in the position
 alpha to the X-X group (i.e. 6 position for a six membered
 aromatic ring etc) by amino, hydroxy, halo, alkyl, carboxy,
 alkoxycarbonyl, cyano, amido, aminoalkyl, alkoxy or alkylthio
 with the proviso that R₂ cannot be aminoisoquinolyl;

20 each X independently is a C, N, O or S atom or a CO,
 CR_{1a}, C(R_{1a})₂ or NR_{1a} group, at least one X being C, CO, CR_{1a}
 or C(R_{1a})₂;

each R_{1a} independently represents hydrogen or hydroxyl,
 alkoxy, alkyl, aminoalkyl, hydroxyalkyl alkoxyalkyl,
 25 alkoxycarbonyl, alkylaminocarbonyl, alkoxycarbonylamino,
 acyloxymethoxycarbonyl or alkylamino optionally substituted by
 hydroxy, alkylamino, alkoxy, oxo, aryl or cycloalkyl;

R₁ is as defined for R_{1a}, provided that R₁ is not
 unsubstituted aminoalkyl;

30 ~~Y (the α atom) is a nitrogen atom or a CR_{1b} group;~~


Cy is a saturated or unsaturated, mono or poly cyclic,
 homo or heterocyclic group, optionally substituted by groups

R_{3a} or phenyl optionally substituted by R_{3a};

each R_{3a} independently is R_{1c}, amino, halo, cyano, nitro, thiol, alkylthio, alkylsulphonyl, alkylsulphenyl, triazolyl, imidazolyl, tetrazolyl, hydrazido, alkyl imidazolyl, thiazolyl, alkyl thiazolyl, alkyl oxazolyl, oxazolyl, alkylsulphonamido, alkylaminosulphonyl, aminosulphonyl, haloalkoxy and haloalkyl;


~~R_{1b}, R_{1c} and R_{1j} are as defined for R_{1a} and~~

-L-Lp(D)_n is of the formula:



in which R_r is -(CH₂)_c-R_c, -CHR_eR_f, -CH₂-CHR_eR_f, or R_g in which c is 1 or 2; R_c is pyridyl or phenyl (which phenyl may bear a fluoro, chloro, methyl, CONH₂, SO₂NH₂, methylaminosulphonyl, dimethylaminosulphonyl, methoxy or methylsulphonyl substituent); each of R_e and R_f independently is hydrogen or C₁₋₃alkyl; or CHR_eR_f is cyclopentyl (which may bear a methyl, ethyl or hydroxymethyl substituent at the 3- or 4-position), cyclohexyl (which may bear a methyl, ethyl or hydroxymethyl, (1-3C)alkyl, carboxy, methoxycarbonyl or ethoxycarbonyl substituent at the 3- or 4-position), tetrahydropyran-4-yl, tetrahydrothiopyran-4-yl, pyrrolidin-3-yl (which may bear a 1-methyl substituent), or indan-2-yl; and R_g is 2-methylsulphonylphenyl which may bear a 4-fluoro substituent or R_g is λ⁶-1,1-dioxobenzo[b]thiophen-7-yl.

~~or a physiologically tolerable salt thereof, provided that Lp(D)_n is not of the formula (K):~~




- 175 -

(K)

~~wherein X₂ is fluoro or hydrogen.~~

- 5 3. A compound according to claim 1 wherein -L-Lp(D)_n is of the formula:



- in which R_r is -(CH₂)_c-R_c; in which c is 2; R_c is
 thienyl, thiazolyl (which may bear an amino substituent),
 10 isothiazolyl, oxazolyl, isoxazolyl, pyrazolyl, imidazolyl,
 pyridyl (which may bear an amino, methoxycarbonyl, carboxy,
 fluoro, cyano, methyl, methylsulphonyl, aminosulphonyl,
 methylaminosulfonyl, dimethylaminosulfonyl, or trifluoromethyl
 substituent), pyrimidinyl, pyridazinyl, pyrazinyl or phenyl
 15 (which phenyl may bear a fluoro, chloro, cyano, methyl, amino,
 methylsulphonyl, aminosulphonyl, methylaminosulphonyl,
 dimethylaminosulphonyl, methylamino, dimethylamino, carboxy,
 methoxycarbonyl or methoxy substituent).

(amended)

- 20 4. A compound according to ~~any one of claims 1 to 3~~ wherein
 R_c is thiazolyl (which may bear an amino substituent),
 pyrimidinyl, pyrazolyl, imidazolyl, pyridyl (which may bear a
 methylsulphonyl, aminosulphonyl, methylaminosulfonyl,
 dimethylaminosulfonyl, fluoro, cyano, methyl or
 25 trifluoromethyl substituent), pyridazinyl, pyrazinyl or phenyl
 (which phenyl may bear a fluoro, chloro, cyano, methyl, amino,
 methylamino, dimethylamino, carboxy, methoxycarbonyl,
 methylsulphonyl, aminosulphonyl, methylaminosulfonyl,
 dimethylaminosulfonyl, or methoxy substituent).

(amended)

- 30 5. A compound according to ~~any one of claims 1 to 4~~ wherein

Rc is thiazolyl (which may bear an amino substituent), pyrazolyl, imidazolyl, pyridyl (which may bear a fluoro, cyano, methyl or trifluoromethyl substituent), pyridazinyl or pyrazinyl.







5 (amended)

6. A compound according to ~~any one of claims 1 to 5~~ wherein Rc is thiazol-2-yl, 2-aminothiazol-4-yl, pyrazol-1-yl, pyrazol-4-yl, pyridazin-3-yl, imidazol-1-yl, imidazol-4-yl, pyrazin-2-yl, pyrid-2-yl, pyrid-3-yl, pyrid-4-yl, 3-fluoropyrid-4-yl, 2-cyanopyrid-4-yl, 2-methylpyrid-4-yl or 2-trifluoromethylpyrid-6-yl.










(amended)

L is CO and

7. A compound according to claim 1 wherein -Lp(D)n is of the formula:



- 177 -




204020 4970001

5

10

- 178 -



wherein;


m represents 0 or 1;

5 X^0 represents CH or N; and


when R_3 is present as a substituent on an aromatic ring,
 it is selected from hydrogen, alkylsulphonyl, aminosulphonyl,
 alkylaminosulphonyl, alkylaminocarbonyl, amino, amido,
 alkoxycarbonyl, acetyl amino, chloro, fluoro, cyano, methoxy,
 10 ethoxy, nitro, hydroxy, alkylsulphonylamino, triazolyl and
 tetrazolyl; and

when R_3 is present as a substituent on a saturated ring,
 it is selected from hydrogen, hydroxy, amino, (1-3C)alkoxy,
 (1-3C)hydroxyalkyl, (1-3C)alkyl, carboxy, methoxycarbonyl and
 15 ethoxycarbonyl.

8. A compound according to claim 7 wherein $-Lp(D)n$ is of the
 formula:



- 179 -



wherein R_1 is hydrogen or (1-6C)alkyl.

(amended)


9. A compound according to ~~any one of claims 1 to 8~~ wherein R_2 is phenyl, thien-2-yl, naphthyl, indol-2-yl, indol-6-yl, benzo[b]furan-5-yl, benzo[b]thiophen-2-yl or benzimidazol-2-yl (each of which is optionally substituted as defined in claim 1).

(amended)

10. A compound according to ~~any one of claims 1 to 9~~ wherein optional substituents for R_2 are selected from: fluoro, chloro, bromo, iodo, nitro, thiol, difluoromethoxy, trifluoromethoxy, hydrazido, methylhydrazido, amino, cyano, trifluoromethyl, methylthio, vinyl, ethynyl, acetylamino, carboxy, acetoxy, hydroxy, methyl, ethyl, amido (CONH_2), aminomethyl, methoxy and ethoxy.

(amended)

11. A compound according to ~~any one of claims 1 to 10~~ wherein R_2 is selected from one of the formula (A') to (H'):



wherein X_4 is O or S, R_{13} is selected from hydrogen, fluoro, [except for (C')] chloro or methyl and R_{14} is selected from hydrogen, methyl, ethyl, fluoro, chloro, and methoxy and
 5 R_{15} is selected from hydrogen, methyl, fluoro, chloro and amino.

(amended)

12. A compound according to claims ~~1 to 11~~, wherein R_2 is 4-chlorophenyl, 4-methoxyphenyl, 3-amino-4-chlorophenyl, indol-
 10 2-yl, 5-chloroindol-2-yl, indol-6-yl, 3-chloroindol-6-yl or 3-methylindol-6-yl.

(amended)

13. A compound according to ~~any one of claims 1 to 12~~ wherein

-X-X- is -CONH-.

(amended)

, 15 to 16 and 19 to 22

14. A compound according to any one of claims 1 to 13 wherein Y is CH.

5 (amended)

15. A compound according to ~~any one of claims 1 to 14~~ wherein Cy is an optionally R_{3a} substituted: phenyl, pyridyl, thienyl, thiazolyl, naphthyl, piperidinyl, furanyl, pyrrolyl, isoxazolyl, isothiazolyl, pyrazolyl, oxazolyl, imidazolyl, 1,2,4-thiadiazolyl, 1,3,4-thiadiazolyl, pyrimidinyl, pyridazinyl, quinolyl, isoquinolyl, benzofuryl, benzothienyl or cycloalkyl group, or a phenyl group substituted by R_{3i}X_i in which X_i is a bond, O, NH or CH₂ and R_{3i} is phenyl, pyridyl or pyrimidyl optionally substituted by R_{3a}.

15 (amended)

2

16. A compound according to ~~any one of claims 1 to 14~~ wherein Cy is an optionally R_{3a} substituted: phenyl, pyridyl, thienyl, thiazolyl, naphthyl, piperidinyl or cycloalkyl group.

(cancelled on national phase entry)

20 17. ~~A compound according to any one of claims 1 to 16 wherein~~
R_{3a} is selected from hydrogen, hydroxyl, alkoxy, alkyl (optionally substituted by hydroxy, alkylamino, alkoxy, oxo, aryl or cycloalkyl), aminoalkyl (optionally substituted by hydroxy, alkylamino, alkoxy, oxo, aryl or cycloalkyl),
25 hydroxyalkyl (optionally substituted by hydroxy, alkylamino, alkoxy, oxo, aryl or cycloalkyl), alkoxyalkyl, alkoxycarbonyl, alkylaminocarbonyl, alkoxycarbonylamino, alkylamino (optionally substituted by hydroxy, alkylamino, alkoxy, oxo, aryl or cycloalkyl), amino, halo, cyano, nitro, thiol,
30 alkylthio, alkylsulphonyl, alkylsulphenyl, alkylsulphonamido, alkylaminosulphonyl, aminosulphonyl, haloalkoxy, haloalkyl, a group of the formula -C(X³)N(R¹¹)R¹² (wherein X³ is O or S; and R¹¹ and R¹² are independently selected from hydrogen, methyl or ethyl or together with the nitrogen atom to which

- 182 -

~~they are attached form a pyrrolidin-1-yl, piperidin-1-yl or morpholino group) and -OCH₂O- which is bonded to two adjacent ring atoms in Cy~~

(cancelled on national phase entry)

- 5 18. ~~A compound according to any one of claims 1 to 16 wherein~~
~~R_{3a} is selected from hydrogen, hydroxyl, alkoxy, alkyl~~
~~(optionally substituted by hydroxy, alkylamino, alkoxy, oxo,~~
~~aryl or cycloalkyl), hydroxyalkyl (optionally substituted by~~
~~hydroxy, alkylamino, alkoxy, oxo, aryl or cycloalkyl),~~
10 ~~alkoxyalkyl, alkoxycarbonyl, alkylaminocarbonyl,~~
~~alkoxycarbonylamino, alkylamino (optionally substituted by~~
~~hydroxy, alkylamino, alkoxy, oxo, aryl or cycloalkyl),~~
~~aminoalkyl (substituted by hydroxy, alkylamino, alkoxy, oxo,~~
~~aryl or cycloalkyl), amino, halo, cyano, nitro, thiol,~~
15 ~~alkylthio, alkylsulphonyl, alkylsulphenyl, alkylsulphonamido,~~
~~alkylaminosulphenyl, aminosulphonyl, haloalkoxy and haloalkyl~~

(amended)

15


19. ~~A compound according to any one of claims 1 to 16 wherein~~
~~R_{3a} is selected from hydrogen, hydroxyl, methoxy, ethoxy,~~
20 ~~methyl, ethyl, methylaminomethyl, dimethylaminomethyl,~~
~~hydroxymethyl, carboxy, methoxymethyl, methoxycarbonyl,~~
~~ethoxycarbonyl, methylaminocarbonyl, dimethylamino-carbonyl,~~
~~aminomethyl, CONH₂, CH₂CONH₂, acetyl amino,~~
~~methoxycarbonylamino, ethoxycarbonylamino, t-~~
25 ~~butoxycarbonylamino, amino, fluoro, chloro, bromo, cyano,~~
~~nitro, thiol, methylthio, methylsulphonyl, ethylsulphonyl,~~
~~methylsulphenyl, methylsulphonylamido, ethylsulphonylamido,~~
~~methylaminosulphonyl, ethylaminosulphonyl, aminosulphonyl,~~
~~trifluoromethoxy, trifluoromethyl, bromo, -OCH₂O- (which is~~
30 ~~bonded to two adjacent ring atoms in Cy) and -C(X³)N(R¹¹)R¹²~~
~~(wherein X³ is O or S and R¹¹ and R¹² are independently~~
~~selected from hydrogen, methyl or ethyl or together with the~~
~~nitrogen atom to which they are attached form a pyrrolidin-1-~~
~~yl, piperidin-1-yl or morpholino group).~~

(amended)

20. A compound according to ~~any one of claims 1 to 16~~ wherein R_{3a} is selected from hydrogen, hydroxyl, methoxy, ethoxy, methyl, ethyl, methylaminomethyl, dimethylaminomethyl, hydroxymethyl, carboxy, methoxymethyl, methoxycarbonyl, ethoxycarbonyl, methylaminocarbonyl, dimethylamino-carbonyl, aminomethyl, $CONH_2$, CH_2CONH_2 , acetyl amino, methoxycarbonylamino, ethoxycarbonylamino, t-butoxycarbonylamino, amino, fluoro, chloro, cyano, nitro, thiol, methylthio, methylsulphonyl, ethylsulphonyl, methylsulphenyl, methylsulphonylamido, ethylsulphonylamido, methylaminosulphonyl, ethylaminosulphonyl, aminosulphonyl, trifluoromethoxy and trifluoromethyl.

(amended)

21. A compound according to ~~any one of claims 1 to 14~~ wherein Cy is selected from:



wherein:

X' is selected from O, S and NMe;

X'' is selected from O and S;

X''' is selected from O, S, NH and NMe;

Y' is selected from hydrogen, amino and methyl;

R_o is selected from hydrogen, methyl, fluoro, chloro, trifluoromethyl, methoxy, methylthio, methylsulphanyl and methylsulphonyl;

R_m is selected from hydrogen, methyl, fluoro, chloro, trifluoromethyl, methoxy, methylthio, methylsulphanyl, methylsulphonyl, carboxy, methoxycarbonyl and a group of the formula -C(X³)N(R¹¹)R¹² (wherein X³ is O or S and R¹¹ and R¹² are independently selected from hydrogen, methyl or ethyl or together with the nitrogen atom to which they are attached form a pyrrolidin-1-yl, piperidin-1-yl or morpholino group); R_p is selected from hydrogen and fluoro; or

R_O and R_m or R_m and R_p form an $-OCH_2O-$ group; or
 R_O and R_m together with the ring to which they are attached
 form a 5 or 6 membered aryl or heteroaryl ring (wherein the
 heteroaryl ring contains 1 or 2 heteroatoms selected from
 5 nitrogen, oxygen and sulfur);


one of R_{O1} and R_{O2} is hydrogen and the other is R_O ;

(amended)

22. A compound according to ~~any one of claims 1 to 14~~ wherein
 Cy is selected from phenyl, 2-chlorophenyl, 2-methoxyphenyl,
 10 4-carbamoylphenyl, pyrid-2-yl, pyrid-4-yl, thien-2-yl, thien-
 3-yl, furan-2-yl, furan-3-yl, imidazol-2-yl, thiazol-2-yl,
 thiazol-4-yl, thiazol-5-yl and quinolin-4-yl.

(amended)


23. A compound of the formula:



or a physiologically-tolerable salt thereof, wherein Cy, R_2
 and R_c are as defined in ~~any one of claims 1 to 22~~.

(amended)

24. A compound of the formula:



or a physiologically-tolerable salt thereof, wherein Cy and R_2
 are as defined in ~~any one of claims 1 to 22~~.

(amended)

25. A compound as claimed in ~~any one of Claims 1 to 24~~, in
 which the alpha atom in Y is carbon and has the conformation
 that would result from construction from a D- α -amino acid
 $NH_2-CR_{1b}(Cy)-COOH$ where the NH_2 represents part of X-X.

26. A compound as claimed in Claim 1, which is selected from:
 1-(Indole-6-carbonyl-D-phenylglyciny1)-4-[2-(4-pyridiny1)-ethyl]piperazine;
 5 1-(3-Chloroindole-6-carbonyl-D-phenylglyciny1)-4-[2-(4-pyridiny1)ethyl]piperazine;
 1-(4-Methoxybenzoyl-D-phenylglyciny1)-4-(1-methylpiperidin-4-yl)piperazine;
 1-(Indole-6-carbonyl-D-phenylglyciny1)-4-(1-methylpiperidin-4-yl)piperazine;
 10 1-(4-Methoxybenzoyl-D-(2-chlorophenyl)glyciny1)-4-(1-methylpiperidin-4-yl)piperazine;
 1-(Indole-6-carbonyl-D-(2-chlorophenyl)glyciny1)-4-(1-methylpiperidin-4-yl)piperazine; and
 15 1-(4-Methoxybenzoyl-D-(2-trifluoromethylphenyl)glyciny1)-4-(1-methylpiperidin-4-yl)piperazine;
 and physiologically-tolerable salts thereof.

- (amended)*
 27. A pharmaceutical composition, which comprises a compound
 20 as claimed in ~~any one of Claims 1 to 26~~ together with at least one pharmaceutically acceptable carrier or excipient.

- (cancelled on national phase entry)*
 28. ~~A compound as claimed in any one of Claims 1 to 26, for use in therapy.~~

- 25 *(cancelled on national phase entry)*
 29. ~~Use of a compound as claimed in any one of Claims 1 to 26 for the manufacture of a medicament for the treatment of a thrombotic disorder.~~

- 30 30. A method of treatment of a human or non-human animal body to combat a thrombotic disorder, which comprises administering to said body an effective amount of a compound as claimed in claim 1.

(cancelled on national phase entry)


31. ~~A pharmaceutical composition comprising a compound as claimed in any one of claims 1 to 26 for use to combat a thrombotic disorder.~~

(cancelled on national phase entry)

5 32. ~~A compound of formula I as claimed in claim 1 and named in any of the Examples herein, or a physiologically tolerable salt thereof.~~

(amended)

10 33. A compound of the formula



or a salt thereof.

in which Cy is as defined in claim 1,

204020-287000

accompanying application as follows:

Please add the Abstract attached on a separate sheet.

In the Claims

Please cancel Claims 17, 18, 28, 29, 31 and 32 (without prejudice); enter the indicated amendments to Claims 2, 4 to 7, 9 to 16, 19 to 25, 27 and 33; and enter new Claims 34 to 36. Directions for amendment of claims are indicated on the copy of the attached hand amended ("marked up") original claims, showing in manuscript the amendments that have been made and the origins of the new claims. Clean forms of new and rewritten claims are included in the attached "Clean Set of Claims" document.

Remarks

This application seeks protection for certain novel compounds that are inhibitors of the serine protease, Factor Xa, and are useful for the treatment of thrombotic disorders. It is the national stage of an international application, the claims of which were drafted in accordance with international practice.

Applicants now wish to amend the application to bring it into conformity with United States patent practice.

For the assistance of the Examiner, a copy of the original claims is attached, as noted above, showing in manuscript the amendments that have been made.

Claims 17, 18, 28, 29, 31 and 32 have been cancelled, without prejudice.

Claims 2, 4 to 6, 9 to 13, 15 to 16, 19 to 24, 27 and 33 have been rewritten in single dependent form.

Claim 2 has been further amended by inserting the value "piperidin-4-yl (which may bear a 1-methyl

substituent,)" in the definition of CHR_eR_f before "or indan-2-yl". Basis for this amendment may be found in the corresponding passage at page 8, lines 22 to 23 of the description.

Claim 7 has been amended by inserting a definition for L, based upon page 11, line 16.

Claim 14 now depends from any one of claims 1 to 13, 15 to 16 and 19 to 22. Claim 25 now depends from claim 14.

New claim 34 is based upon Claim 26 and is directed to a single compound, 1-(Indole-6-carbonyl-D-phenylglyciny)-4-(1-methylpiperidin-4-yl)piperazine and its physiologically tolerable salts. New Claim 35 is based upon Claim 27, and is directed to a pharmaceutical composition comprising a compound of new Claim 34. Similarly, new Claim 36 is based upon Claim 30, and is directed to a method of combating a thrombotic disorder using a compound of new Claim 34.

For the convenience of the Examiner, it is noted that the compounds of new Claim 34 correspond with formula (I) in Claim 1 in which R_2 is indol-6-yl, X-X is CONH, Y is CH and has the D-configuration, Cy is phenyl and R_f is $-\text{CHR}_e\text{R}_f$ in which CHR_eR_f is piperidin-4-yl that bears a methyl group at the 1-position. Currently Claims 1, 2, 7 to 16, 19 to 22, 24 to 27, 30 and 34 to 36 read on these compounds. Claim 33 reads on an intermediate useful in the preparation of these compounds.

Favorable consideration of the application is requested.

National Phase PCT/GB01/02553

Respectfully submitted,

Mart Alexander Hay

Hay, Martin Alexander

Agent for Applicants

Registration No. 39,459

Phone: 011 44 1625 500057

Martin A. Hay & Co.,
13 Queen Victoria Street
Macclesfield
Cheshire
SK11 6LP
UNITED KINGDOM

February 1, 2002


Attachments: Abstract on separate sheet
Hand-amended (marked-up) Claims
Clean Pending Claims

10/030187

JCS Rec'd PCT/PTO 04 FEB 2002

A B S T R A C T

Compounds of formula (I)



(I)

in which R_2 , X, Y, Cy, L and Lp(D)_n have the meanings given in the specification, are inhibitors of the serine protease, Factor Xa and are useful in the treatment of cardiovascular disorders.


10030187.020402

2002 Rec'd PGT/PTO 04 FEB 2002

- 1 -

Clean Set of Claims

1. A serine protease inhibitor compound of formula (I)



(I)

wherein:

R₂ is a 5 or 6 membered aromatic carbon ring optionally interrupted by a nitrogen, oxygen or sulphur ring atom, optionally being substituted in the 3 and/or 4 position (in relation to the point of attachment of X-X) by halo, nitro, thiol, haloalkoxy, hydrazido, alkylhydrazido, amino, cyano, haloalkyl, alkylthio, alkenyl, alkynyl, acylamino, tri or difluoromethoxy, carboxy, acyloxy, MeSO₂- or R₁, or the substituents at the 3 and 4 positions taken together form a fused ring which is a 5 or 6 membered carbocyclic or heterocyclic ring optionally substituted by halo, haloalkoxy, haloalkyl, cyano, nitro, amino, hydrazido, alkylthio, alkenyl, alkynyl or R_{1j}, and optionally substituted in the position alpha to the X-X group (i.e. 6 position for a six membered aromatic ring etc) by amino, hydroxy, halo, alkyl, carboxy, alkoxy, carbonyl, cyano, amido, aminoalkyl, alkoxy or alkylthio with the proviso that R₂ cannot be aminoisquinolyl;

each X independently is a C, N, O or S atom or a CO,
25 CR_{1a}, C(R_{1a})₂ or NR_{1a} group, at least one X being C, CO, CR_{1a}
or C(R_{1a})₂;

each R_{1a} independently represents hydrogen or hydroxyl, alkoxy, alkyl, aminoalkyl, hydroxyalkyl alkoxyalkyl, alkoxycarbonyl, alkylaminocarbonyl, alkoxycarbonylamino, 30 acyloxymethoxycarbonyl or alkylamino optionally substituted by hydroxy, alkylamino, alkoxy, oxo, aryl or cycloalkyl;

R₁ is as defined for R_{1a}, provided that R₁ is not unsubstituted aminoalkyl;

Y (the α -atom) is a nitrogen atom or a CR_{1b} group;
35 Cy is a saturated or unsaturated, mono or poly cyclic,
homo or heterocyclic group, optionally substituted by groups

- 2 -

R_{3a} or $R_{3i}X_i$;


each R_{3a} independently is R_{1c} , amino, halo, cyano, nitro, thiol, alkylthio, alkylsulphonyl, alkylsulphenyl, triazolyl, imidazolyl, tetrazolyl, hydrazido, alkylimidazolyl, thiazolyl, 5 alkylthiazolyl, alkyloxazolyl, oxazolyl, alkylsulphonamido, alkylaminosulphonyl, aminosulphonyl, haloalkoxy, haloalkyl, a group of the formula $-C(X^3)N(R^{11})R^{12}$ (wherein X^3 is O or S; and R^{11} and R^{12} are independently selected from hydrogen, methyl or ethyl or together with the nitrogen atom to which 10 they are attached form a pyrrolidin-1-yl, piperidin-1-yl or morpholino group), or $-OCH_2O-$ which is bonded to two adjacent ring atoms in Cy;

X_i is a bond, O, NH or CH_2 ;

R_{3i} is phenyl, pyridyl or pyrimidinyl optionally 15 substituted by R_{3a} ;

R_{1b} , R_{1c} and R_{1j} are as defined for R_{1a} ; and

$-L-Lp(D)_n$ is of the formula:




in which R_r is $-(CH_2)_c-R_c$, $-CHR_eR_f$, $-CH_2-CHR_eR_f$, 20 $-CH_2-CH_2-CHR_eR_f$, or R_g in which c is 1 or 2; R_c is thienyl, thiazolyl (which may bear an amino substituent), isothiazolyl, oxazolyl, isoxazolyl, pyrazolyl, imidazolyl, pyridyl (which may bear an alkylsulphonyl, aminosulphonyl, alkylaminosulphonyl, alkylaminocarbonyl, amino, amido, (1- 25 4C)alkoxycarbonyl, carboxy, acetyl amino, chloro, fluoro, cyano, (1-3C)alkyl, trifluoromethyl, methoxy, ethoxy, nitro, hydroxy, alkylsulphonylamino, triazolyl or tetrazolyl substituent), pyrimidinyl, pyridazinyl, pyrazinyl or phenyl (which may bear a methyl, methylamino, dimethylamino, carboxy, 30 dialkylaminosulphonyl, alkylsulphonyl, aminosulphonyl, alkylaminosulphonyl, alkylaminocarbonyl, amino, amido, alkoxycarbonyl, acetyl amino, chloro, fluoro, cyano, methoxy, ethoxy, nitro, hydroxy, alkylsulphonylamino, triazolyl or tetrazolyl substituent); each of R_e and R_f independently is 35 hydrogen or C_{1-3} alkyl; or CHR_eR_f is cyclopentyl (which may

10030187.020402

- 3 -

bear a hydroxy, amino, (1-3C)alkoxy, (1-3C)hydroxyalkyl, (1-3C)alkyl, carboxy, methoxycarbonyl or ethoxycarbonyl substituent at the 3- or 4-position), cyclohexyl (which may bear a hydroxy, amino, (1-3C)alkoxy, (1-3C)hydroxyalkyl, (1-3C)alkyl, carboxy, methoxycarbonyl or ethoxycarbonyl substituent at the 3- or 4-position), tetrahydropyran-4-yl, tetrahydrothiopyran-4-yl, pyrrolidin-3-yl (which may bear a hydroxy, amino, (1-3C)alkoxy, (1-3C)hydroxyalkyl, (1-3C)alkyl, carboxy, methoxycarbonyl or ethoxycarbonyl substituent at the 1-position), piperidin-4-yl (which may bear a hydroxy, amino, (1-3C)alkoxy, (1-3C)hydroxyalkyl, (1-3C)alkyl, carboxy, methoxycarbonyl or ethoxycarbonyl substituent at the 1-position), or indan-2-yl; and R_G is 2-methylsulphonylphenyl which may bear a 4-fluoro substituent or R_G is λ^6 -1,1-dioxobenzob[b]thiophen-7-yl;

or a physiologically-tolerable salt thereof;
provided that $Lp(D)_n$ is not of the formula (K):



wherein X_2 is fluoro or hydrogen.


2. (amended) A compound according to claim 1
wherein

Cy is a saturated or unsaturated, mono or poly cyclic, homo or heterocyclic group, optionally substituted by groups R_{3a} or phenyl optionally substituted by R_{3a} ;

each R_{3a} independently is R_{1C} , amino, halo, cyano, nitro, thiol, alkylthio, alkylsulphonyl, alkylsulphenyl, triazolyl, imidazolyl, tetrazolyl, hydrazido, alkyl imidazolyl, thiazolyl, alkyl thiazolyl, alkyl oxazolyl, oxazolyl, alkylsulphonamido, alkylaminosulphonyl, aminosulphonyl, haloalkoxy and haloalkyl; and

-L- $Lp(D)_n$ is of the formula:


- 4 -



in which R_r is $-(CH_2)_c-R_c$, $-CHR_eR_f$, $-CH_2-CHR_eR_f$, or R_g in which c is 1 or 2; R_c is pyridyl or phenyl (which phenyl may bear a fluoro, chloro, methyl, $CONH_2$, SO_2NH_2 ,

5 methylaminosulphonyl, dimethylaminosulphonyl, methoxy or methylsulphonyl substituent); each of R_e and R_f independently is hydrogen or C_{1-3} alkyl; or CHR_eR_f is cyclopentyl (which may bear a methyl, ethyl or hydroxymethyl substituent at the 3- or 4-position), cyclohexyl (which may bear a methyl, ethyl or
10 hydroxymethyl, (1-3C)alkyl, carboxy, methoxycarbonyl or ethoxycarbonyl substituent at the 3- or 4-position), tetrahydropyran-4-yl, tetrahydrothiopyran-4-yl, pyrrolidin-3-yl (which may bear a 1-methyl substituent), piperidin-4-yl (which may bear a 1-methyl substituent), or indan-2-yl; and R_g
15 is 2-methylsulphonylphenyl which may bear a 4-fluoro substituent or R_g is λ^6 -1,1-dioxobenzo[b]thiophen-7-yl.

3. A compound according to claim 1 wherein $-L-Lp(D)_n$ is of the formula:



20

in which R_r is $-(CH_2)_c-R_c$; in which c is 2; R_c is thienyl, thiazolyl (which may bear an amino substituent), isothiazolyl, oxazolyl, isoxazolyl, pyrazolyl, imidazolyl, pyridyl (which may bear an amino, methoxycarbonyl, carboxy,
25 fluoro, cyano, methyl, methylsulphonyl, aminosulphonyl, methylaminosulfonyl, dimethylaminosulfonyl, or trifluoromethyl substituent), pyrimidinyl, pyridazinyl, pyrazinyl or phenyl (which phenyl may bear a fluoro, chloro, cyano, methyl, amino, methylsulphonyl, aminosulphonyl, methylaminosulphonyl,
30 dimethylaminosulphonyl, methylamino, dimethylamino, carboxy, methoxycarbonyl or methoxy substituent).


- 5 -

4. (amended) A compound according to claim 3 wherein R_c is thiazolyl (which may bear an amino substituent), pyrimidinyl, pyrazolyl, imidazolyl, pyridyl (which may bear a methylsulphonyl, aminosulphonyl, methylaminosulfonyl, dimethylaminosulfonyl, fluoro, cyano, methyl or trifluoromethyl substituent), pyridazinyl, pyrazinyl or phenyl (which phenyl may bear a fluoro, chloro, cyano, methyl, amino, methylamino, dimethylamino, carboxy, methoxycarbonyl, methylsulphonyl, aminosulphonyl, methylaminosulfonyl, dimethylaminosulfonyl, or methoxy substituent).












5. (amended) A compound according to claim 4 wherein R_c is thiazolyl (which may bear an amino substituent), pyrazolyl, imidazolyl, pyridyl (which may bear a fluoro, cyano, methyl or trifluoromethyl substituent), pyridazinyl or pyrazinyl.

6. (amended) A compound according to claim 5 wherein R_c is thiazol-2-yl, 2-aminothiazol-4-yl, pyrazol-1-yl, pyrazol-4-yl, pyridazin-3-yl, imidazol-1-yl, imidazol-4-yl, pyrazin-2-yl, pyrid-2-yl, pyrid-3-yl, pyrid-4-yl, 3-fluoropyrid-4-yl, 2-cyanopyrid-4-yl, 2-methylpyrid-4-yl or 2-trifluoromethylpyrid-6-yl.

7. (amended) A compound according to claim 1 wherein L is CO and -Lp(D)_n is of the formula:



- 6 -




10030187 020400

5

10

- 7 -



wherein;

m represents 0 or 1;


X^0 represents CH or N; and

when R_3 is present as a substituent on an aromatic ring, it is selected from hydrogen, alkylsulphonyl, aminosulphonyl, alkylaminosulphonyl, alkylaminocarbonyl, amino, amido, alkoxy, alkoxy, nitro, hydroxy, alkylsulphonylamino, triazolyl and tetrazolyl; and

when R_3 is present as a substituent on a saturated ring, it is selected from hydrogen, hydroxy, amino, (1-3C)alkoxy, (1-3C)hydroxyalkyl, (1-3C)alkyl, carboxy, methoxycarbonyl and ethoxycarbonyl.

8. A compound according to claim 7 wherein $-Lp(D)_n$ is of the formula:

- 8 -



wherein R_1 is hydrogen or (1-6C)alkyl.

5

9. (amended) A compound according to claim 1 wherein R_2 is phenyl, thien-2-yl, naphthyl, indol-2-yl, indol-6-yl, benzo[b]furan-5-yl, benzo[b]thiophen-2-yl or benzimidazol-2-yl (each of which is optionally substituted as defined in claim


10 1).

10. (amended) A compound according to claim 9 wherein optional substituents for R_2 are selected from:

fluoro, chloro, bromo, iodo, nitro, thiol, difluoromethoxy, trifluoromethoxy, hydrazido, methylhydrazido, amino, cyano, trifluoromethyl, methylthio, vinyl, ethynyl, acetylamino, carboxy, acetoxy, hydroxy, methyl, ethyl, amido (CONH_2), aminomethyl, methoxy and ethoxy.

20 11. (amended) A compound according to claim 1 wherein R_2 is selected from one of the formula (A') to (H'):

- 9 -



wherein X_4 is O or S, R_{13} is selected from hydrogen, fluoro, [except for (C')] chloro or methyl and R_{14} is selected from hydrogen, methyl, ethyl, fluoro, chloro, and methoxy and
 5 R_{15} is selected from hydrogen, methyl, fluoro, chloro and amino.

12. (amended) A compound according to claim 11, wherein R_2 is 4-chlorophenyl, 4-methoxyphenyl, 3-amino-4-chlorophenyl,
 10 indol-2-yl, 5-chloroindol-2-yl, indol-6-yl, 3-chloroindol-6-yl or 3-methylindol-6-yl.

13. (amended) A compound according to claim 1 wherein -X-X- is -CONH-.

- 10 -

14. (amended) A compound according to any one of claims 1 to 13, 15 to 16 and 19 to 22 wherein Y is CH.

15. (amended) A compound according to claim 1 wherein Cy is
5 an optionally R_{3a} substituted: phenyl, pyridyl, thienyl, thiazolyl, naphthyl, piperidinyl, furanyl, pyrrolyl, isoxazolyl, isothiazolyl, pyrazolyl, oxazolyl, imidazolyl, 1,2,4-thiadiazolyl, 1,3,4-thiadiazolyl, pyrimidinyl, pyridazinyl, quinolyl, isoquinolyl, benzofuryl, benzothienyl
10 or cycloalkyl group, or a phenyl group substituted by R_{3i}X_i in which X_i is a bond, O, NH or CH₂ and R_{3i} is phenyl, pyridyl or pyrimidyl optionally substituted by R_{3a}.

16. (amended) A compound according to claim 2 wherein Cy is an
15 optionally R_{3a} substituted: phenyl, pyridyl, thienyl, thiazolyl, naphthyl, piperidinyl or cycloalkyl group.

17. (cancelled on national phase entry)

20 18. (cancelled on national phase entry)

19. (amended) A compound according to claim 15 wherein R_{3a} is selected from hydrogen, hydroxyl, methoxy, ethoxy, methyl, ethyl, methylaminomethyl, dimethylaminomethyl, hydroxymethyl,
25 carboxy, methoxymethyl, methoxycarbonyl, ethoxycarbonyl, methylaminocarbonyl, dimethylamino-carbonyl, aminomethyl, CONH₂, CH₂CONH₂, acetyl amino, methoxycarbonylamino, ethoxycarbonylamino, t-butoxycarbonylamino, amino, fluoro, chloro, bromo, cyano, nitro, thiol, methylthio,
30 methylsulphonyl, ethylsulphonyl, methylsulphenyl, methylsulphonylamido, ethylsulphonylamido, methylaminosulphonyl, ethylaminosulphonyl, aminosulphonyl, trifluoromethoxy, trifluoromethyl, bromo, -OCH₂O- (which is bonded to two adjacent ring atoms in Cy) and -C(X³)N(R¹¹)R¹²
35 (wherein X³ is O or S and R¹¹ and R¹² are independently selected from hydrogen, methyl or ethyl or together with the nitrogen atom to which they are attached form a pyrrolidin-1-yl, piperidin-1-yl or morpholino group).

- 11 -


20. (amended) A compound according to claim 16 wherein R_{3a} is
selected from hydrogen, hydroxyl, methoxy, ethoxy, methyl,
ethyl, methylaminomethyl, dimethylaminomethyl, hydroxymethyl,
5 carboxy, methoxymethyl, methoxycarbonyl, ethoxycarbonyl,
methylaminocarbonyl, dimethylamino-carbonyl, aminomethyl,
CONH₂, CH₂CONH₂, acetyl amino, methoxycarbonylamino,
ethoxycarbonylamino, t-butoxycarbonylamino, amino, fluoro,
chloro, cyano, nitro, thiol, methylthio, methylsulphonyl,
10 ethylsulphonyl, methylsulphenyl, methylsulphonylamido,
ethylsulphonylamido, methylaminosulphonyl,
ethylaminosulphonyl, aminosulphonyl, trifluoromethoxy and
trifluoromethyl.

15 21. (amended) A compound according to claim 1 wherein Cy is
selected from:

20

10030187-020402

- 12 -



wherein:

X' is selected from O, S and NMe;

X'' is selected from O and S;

X''' is selected from O, S, NH and NMe;

Y' is selected from hydrogen, amino and methyl;

R_O is selected from hydrogen, methyl, fluoro, chloro, trifluoromethyl, methoxy, methylthio, methylsulphinyl and methylsulphonyl;

R_m is selected from hydrogen, methyl, fluoro, chloro, trifluoromethyl, methoxy, methylthio, methylsulphinyl, methylsulphonyl, carboxy, methoxycarbonyl and a group of the formula -C(X³)N(R¹¹)R¹² (wherein X³ is O or S and R¹¹ and R¹² are independently selected from hydrogen, methyl or ethyl or together with the nitrogen atom to which they are attached form a pyrrolidin-1-yl, piperidin-1-yl or morpholino group);

R_p is selected from hydrogen and fluoro; or

R_O and R_m or R_m and R_p form an -OCH₂O- group; or

R_O and R_m together with the ring to which they are attached

- 13 -


form a 5 or 6 membered aryl or heteroaryl ring (wherein the heteroaryl ring contains 1 or 2 heteroatoms selected from nitrogen, oxygen and sulfur);

one of R_{O1} and R_{O2} is hydrogen and the other is R_O ;

5

22. (amended) A compound according to claim 1 wherein Cy is selected from phenyl, 2-chlorophenyl, 2-methoxyphenyl, 4-carbamoylphenyl, pyrid-2-yl, pyrid-4-yl, thien-2-yl, thien-3-yl, furan-2-yl, furan-3-yl, imidazol-2-yl, thiazol-2-yl, 10 thiazol-4-yl, thiazol-5-yl and quinolin-4-yl.


23. (amended) A compound of the formula:



wherein Cy, R_2 and R_C are as defined in claim 1.

15

24. (amended) A compound of the formula:



wherein Cy and R_2 are as defined in claim 1.

20

25. (amended) A compound as claimed in Claim 14, in which the alpha atom in Y is carbon and has the conformation that would result from construction from a D- α -aminoacid

$NH_2-CR_{1b}(Cy)-COOH$ where the NH_2 represents part of X-X.

25

26. A compound as claimed in Claim 1, which is selected from:
 1-(Indole-6-carbonyl-D-phenylglyciny)-4-[2-(4-pyridinyl)-ethyl]piperazine;
 1-(3-Chloroindole-6-carbonyl-D-phenylglyciny)-
 4-[2-(4-pyridinyl)ethyl]piperazine;
 1-(4-Methoxybenzoyl-D-phenylglyciny)-4-(1-methylpiperidin-4-

30

- 14 -

yl)piperazine;

1-(Indole-6-carbonyl-D-phenylglyciny1)-4-(1-methylpiperidin-4-yl)piperazine;

1-(4-Methoxybenzoyl-D-(2-chlorophenyl)glyciny1)-4-(1-methyl-
5 piperidin-4-yl)piperazine;

1-(Indole-6-carbonyl-D-(2-chlorophenyl)glyciny1)-4-(1-methyl-
piperidin-4-yl)piperazine; and

1-(4-Methoxybenzoyl-D-(2-trifluoromethylphenyl)glyciny1)-4-(1-
methylpiperidin-4-yl)piperazine;

10 and physiologically-tolerable salts thereof.

27. (amended) A pharmaceutical composition, which comprises a
compound as claimed in Claim 1 together with at least one
pharmaceutically acceptable carrier or excipient.

15

28. (cancelled on national phase entry)


29. (cancelled on national phase entry)

20 30. A method of treatment of a human or non-human animal body
to combat a thrombotic disorder, which comprises administering
to said body an effective amount of a compound as claimed in
claim 1.

25 31. (cancelled on national phase entry)

32. (cancelled on national phase entry)

33. (amended) A compound of the formula



30

in which Cy is as defined in Claim 1, or a salt thereof.

34. (new) 1-(Indole-6-carbonyl-D-phenylglyciny1)-4-(1-
methylpiperidin-4-yl)piperazine; or a physiologically-
35 tolerable salt thereof.

-15 -

35. (new) A pharmaceutical composition, which comprises a compound as claimed in Claim 34 together with at least one pharmaceutically acceptable carrier or excipient.

5

36. (new) A method of treatment of a human or non-human animal body to combat a thrombotic disorder, which comprises administering to said body an effective amount of a compound as claimed in claim 34.

10030137 020402